Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 3796

Growing brains can be a tricky process, but growing ones that can make muscles move? That’s an incredible feat. Here’s how scientists did it.

How Close Are We to Farming Human Body Parts? — https://youtu.be/oRHxX9OW9ow.

Cerebral organoids at the air-liquid interface generate nerve tracts with functional output.
https://www2.mrc-lmb.cam.ac.uk/cerebral-organoids-at-the-air…al-output/
“The capacity for this model to be used to investigate the way in which neurons connect up within the brain and with the spinal cord could have important implications for our understanding of a range of diseases. In particular defects in neuronal connectivity are thought to underlie various psychiatric illnesses, including schizophrenia, autism, and depression. ”

Cerebral organoids at the air–liquid interface generate diverse nerve tracts with functional output.

Continue reading “This Lab-Grown Brain Made a Muscle TWITCH, Here’s How” | >

Just a couple of years earlier, in 1963, New Zealand mathematician Roy Kerr found a solution to Einstein’s equation for a rotating black hole. This was a “game changer for black holes,” Giorgi noted in a public lecture given at the virtual 2022 International Congress of Mathematicians. Rotating black holes were much more realistic astrophysical objects than the non-spinning black holes that Karl Schwarzschild had solved the equations for.

“Physicists really had believed for decades that the black hole region was an artifact of symmetry that was appearing in the mathematical construction of this object but not in the real world,” Giorgi said in the talk. Kerr’s solution helped establish the existence of black holes.

In a nearly 1,000-page paper, Giorgi and colleagues used a type of “proof by contradiction” to show that Kerr black holes that rotate slowly (meaning they have a small angular momentum relative to their mass) are mathematically stable. The technique entails assuming the opposite of the statement to be proved, then discovering an inconsistency. That shows that the assumption is false. The work is currently undergoing peer review. “It’s a long paper, so it’s going to take some time,” Giorgi says.

Read more | >

Researchers at Texas A&M University have developed the first molecular therapeutic for Angelman syndrome to advance into clinical development.

In a new article, published today in Science Translational Medicine, Dr. Scott Dindot, an associate professor and EDGES Fellow in the Texas A&M School of Veterinary Medicine and Biomedical Sciences’ (VMBS) Department of Veterinary Pathobiology, and his team share the process through which they developed this novel therapeutic candidate, also known as 4.4.PS.L, or GTX-102. Dindot is also the executive director of molecular genetics at Ultragenyx, which is leading the development of GTX-102.

Angelman syndrome (AS) is a devastating, rare neurogenetic disorder that affects approximately 1 in 15,000 per year; the disorder is triggered by a loss of function of the maternal UBE3A gene in the brain, causing , absent speech, movement or balance disorder, and seizures.

Read more | >

(CNN) — Startup Relativity Space sent what it’s calling the “world’s first 3D-printed rocket” toward space on Wednesday, vaulting it into the upper reaches of the atmosphere. Though, it suffered an engine issue after launch and failed to reach orbit.

Terran 1, a 110-foot-tall (33.5-meter) vehicle designed to haul lightweight satellites into orbital space, lifted off from Cape Canaveral Space Force Station on Florida’s eastern coast at just before 11:30 pm ET. The rocket, powered by super-chilled methane and oxygen, burned a bright blue-green against the night sky.

After the first stage of the rocket — the bottommost portion of the rocket that gives the initial thrust at liftoff — expended its fuel, it detached from the rocket’s upper stage. But the engine meant to propel that portion appeared to ignite only briefly, leaving the rocket without enough power to reach orbit.

Read more | >

Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the U.S., have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in patients with B cell lymphomas. Individualized microbiome information retrieved from patients’ gut microbiomes prior to initiation of CAR T therapy could accurately predict their subsequent responsiveness to therapy, but only in the condition that these patients were not pre-treated with broad spectrum antibiotics.

Increasing evidence from and preclinical experiments suggests that the gut microbiome may modulate the efficacy of T cell-driven cancer immunotherapies, such as immune checkpoint blockade. Immunotherapy with CD19 (CAR)-T cell has opened up new treatment options for with certain forms of refractory and relapsing B-cell leukemias or lymphomas. But the therapy is hampered by considerable heterogeneity in responses. Complete and long-term remission is only achieved in up to 40% of patients.

Researchers from multiple centers in Germany and the United States, led by Eran Elinav, director of the DKFZ-Weizmann Institute of Science Microbiome & Cancer Bridging division, have found that the gut microbiome may modulate the efficacy of CD19 CAR-T cell immunotherapy in patients with B cell leukemias and lymphomas.

Read more | >